|By PR Newswire||
|August 18, 2014 07:20 PM EDT||
FREDERICK, Md., Aug. 18, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices said that its EVP Dr. Deepak Kotak was interviewed by CEOLIVE.TV as part of its Executive Interview Series.
The entire interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel
In the interview Dr. Kotak explains to investors the unique advantages of BioElectronics patented technology to satisfy the unmet medical needs of millions of consumers. He explains how the Company is positioned to serve new, large medical markets with its drug-free, non-invasive technology.
Before joining BioElectronics Dr. Kotak was Chief Medical Officer of TraumaTec, a Houston medical device company, as well as a consultant to the Boss Group and Blackstone Valley Group, two private equity firms.
Dr. Kotak brings a broad medical background and health care perspective to the Company, having practiced as a specialist in intensive care medicine, anesthesia and trauma in a London teaching hospital. Dr. Kotak has also practiced for four years as a civil lawyer. Dr. Kotak holds degrees in medicine from Oxford University and the University of London.
CEOLIVE.TV is an online financial news portal focused on small cap publicly traded companies with a focus on undervalued stocks. Featuring short video interviews with CEOs, CFOs, Board Members and other corporate executives, CEOLIVE.TV gives investors the opportunity to learn about companies directly from the management team as well as access to detailed company profiles, video press releases and sector reports. To learn more, please visit www.ceolive.tv.
About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Forward Looking Statements
Certain information contained in this press release, including any information as to our strategy, plans or future financial or operating performance and other statements that express management's expectations or estimates of future performance, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Action of 1934. All statements, other than statements of historical fact, are forward-looking statements. The words "believe," "expect," "will," "anticipate," "contemplate," "target," "plan," "continue," "budget," "may," "intend," "estimate," "project" and similar expressions identify forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to its plans or operations. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the SEC which can be found at www.sec.gov. There may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
For Investor and Media Inquiries, please contact:
BioElectronics Corporation Investor Relations
E and E Communications
Email: [email protected]
SOURCE BioElectronics Corporation
Jul. 8, 2015 12:00 AM EDT Reads: 2,519
Jul. 7, 2015 10:30 PM EDT Reads: 2,487
Jul. 7, 2015 10:15 PM EDT Reads: 1,205
Jul. 7, 2015 09:30 PM EDT Reads: 1,215
Jul. 7, 2015 08:00 PM EDT Reads: 966
Jul. 7, 2015 07:00 PM EDT Reads: 2,665
Jul. 7, 2015 07:00 PM EDT Reads: 2,632
Jul. 7, 2015 05:45 PM EDT Reads: 2,512
Jul. 7, 2015 05:00 PM EDT Reads: 2,323
Jul. 7, 2015 05:00 PM EDT Reads: 2,287
Jul. 7, 2015 04:45 PM EDT Reads: 1,748
Jul. 7, 2015 04:15 PM EDT Reads: 865
Jul. 7, 2015 04:00 PM EDT Reads: 1,994
In the midst of the widespread popularity and adoption of cloud computing, it seems like everything is being offered “as a Service” these days: Infrastructure? Check. Platform? You bet. Software? Absolutely. Toaster? It’s only a matter of time. With service providers positioning vastly differing offerings under a generic “cloud” umbrella, it’s all too easy to get confused about what’s actually being offered. In his session at 16th Cloud Expo, Kevin Hazard, Director of Digital Content for SoftL...
Jul. 7, 2015 03:45 PM EDT Reads: 2,716
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances from Isomorphic Software and others, it is now feasible to create a rich desktop and tuned mobile experience with a single codebase, without compromising performance or usability.
Jul. 7, 2015 03:45 PM EDT Reads: 1,467